放化疗-话题@MedSci

#放化疗#

163篇内容 | 3982人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1287988, encodeId=ef8a128e98877, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Front Oncol：奈达铂 vs 顺铂为基础的同期放化疗治疗IIB-IVA期宫颈癌患者的疗效和安全性, objectType=article, longId=295133, objectId=e466295133ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e466295133ba, replyNumber=0, likeNumber=124, createdTime=2022-02-06, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e466295133ba, moduleTitle=Front Oncol：奈达铂 vs 顺铂为基础的同期放化疗治疗IIB-IVA期宫颈癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e466295133ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287987, encodeId=c89c128e987a7, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%, objectType=article, longId=295111, objectId=e91429511199, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e91429511199, replyNumber=0, likeNumber=87, createdTime=2022-02-05, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e91429511199, moduleTitle=J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e91429511199)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287985, encodeId=a562128e985ac, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=JAMA Oncol：3期随机试验 | 序贯放化疗 vs 同步放化疗用作早期宫颈癌术后辅助治疗的疗效, objectType=article, longId=293024, objectId=52cc2930249f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52cc2930249f, replyNumber=0, likeNumber=44, createdTime=2021-12-30, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52cc2930249f, moduleTitle=JAMA Oncol：3期随机试验 | 序贯放化疗 vs 同步放化疗用作早期宫颈癌术后辅助治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52cc2930249f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287984, encodeId=e2b8128e98406, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果, objectType=article, longId=293023, objectId=5fe32930236d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fe32930236d, replyNumber=0, likeNumber=52, createdTime=2021-12-30, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fe32930236d, moduleTitle=Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fe32930236d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287986, encodeId=c027128e9862d, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Ann Oncol：局限期小细胞肺癌(LD-SCLC)患者同步放化疗+PCI后使用nivolumab+ipilimumab免疫联合强化治疗并不能改善患者的预后, objectType=article, longId=292797, objectId=618f292e9792, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=618f292e9792, replyNumber=0, likeNumber=96, createdTime=2021-12-28, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=618f292e9792, moduleTitle=Ann Oncol：局限期小细胞肺癌(LD-SCLC)患者同步放化疗+PCI后使用nivolumab+ipilimumab免疫联合强化治疗并不能改善患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=618f292e9792)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287983, encodeId=466f128e983f2, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=JAMA Netw Open：中肿麦海强教授团队证实奈达铂为基础的同期放化疗可作为II-IVB期鼻咽癌患者的有效治疗方案, objectType=article, longId=292561, objectId=7ac929256113, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ac929256113, replyNumber=0, likeNumber=84, createdTime=2021-12-24, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ac929256113, moduleTitle=JAMA Netw Open：中肿麦海强教授团队证实奈达铂为基础的同期放化疗可作为II-IVB期鼻咽癌患者的有效治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ac929256113)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287982, encodeId=9763128e982ed, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=DCR: 慢性肾脏病对接受新辅助放化疗治疗的局部晚期直肠癌患者的预后影响, objectType=article, longId=265010, objectId=4dc6265010cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dc6265010cc, replyNumber=0, likeNumber=66, createdTime=2021-12-14, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dc6265010cc, moduleTitle=DCR: 慢性肾脏病对接受新辅助放化疗治疗的局部晚期直肠癌患者的预后影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dc6265010cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287981, encodeId=7e20128e98187, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Front Oncol：比较同步放化疗联合诱导化疗或辅助化疗在II–IVA期鼻咽癌患者中的疗效和安全性, objectType=article, longId=221519, objectId=836f22151965, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=836f22151965, replyNumber=0, likeNumber=71, createdTime=2021-12-05, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=836f22151965, moduleTitle=Front Oncol：比较同步放化疗联合诱导化疗或辅助化疗在II–IVA期鼻咽癌患者中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=836f22151965)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287980, encodeId=a660128e98019, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=JAMA Oncol：局部晚期结直肠癌的全新辅助疗法——放化疗+诱导/巩固化疗！, objectType=article, longId=221421, objectId=c3fc22142171, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3fc22142171, replyNumber=0, likeNumber=75, createdTime=2021-12-03, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3fc22142171, moduleTitle=JAMA Oncol：局部晚期结直肠癌的全新辅助疗法——放化疗+诱导/巩固化疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3fc22142171)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287979, encodeId=cb07128e9793b, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=EP 方案同步放化疗治疗局限期小细胞肺癌的疗效分析, objectType=article, longId=220674, objectId=456f2206e4cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=456f2206e4cc, replyNumber=0, likeNumber=62, createdTime=2021-11-22, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=456f2206e4cc, moduleTitle=EP 方案同步放化疗治疗局限期小细胞肺癌的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=456f2206e4cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287978, encodeId=9cf8128e978a1, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Front Oncol：新辅助同步放化疗(nCRT)对可切除Siewert II型或III型胃食管交界处腺癌(AEG)的长期疗效影响, objectType=article, longId=220337, objectId=e64222033e7d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e64222033e7d, replyNumber=0, likeNumber=63, createdTime=2021-11-16, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e64222033e7d, moduleTitle=Front Oncol：新辅助同步放化疗(nCRT)对可切除Siewert II型或III型胃食管交界处腺癌(AEG)的长期疗效影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e64222033e7d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287977, encodeId=7c59128e9772d, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=J Clin Oncol：儿童放化疗后，听力损失的发生率和风险因素调查 , objectType=article, longId=219079, objectId=e5c02190e9a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5c02190e9a2, replyNumber=0, likeNumber=78, createdTime=2021-10-24, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5c02190e9a2, moduleTitle=J Clin Oncol：儿童放化疗后，听力损失的发生率和风险因素调查 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5c02190e9a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287976, encodeId=e3f1128e9769e, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Cancers：早期乳腺癌患者新辅助放化疗的长期疗效和安全性, objectType=article, longId=218811, objectId=ff98218811b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff98218811b1, replyNumber=0, likeNumber=71, createdTime=2021-10-20, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff98218811b1, moduleTitle=Cancers：早期乳腺癌患者新辅助放化疗的长期疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff98218811b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287975, encodeId=3e14128e975e8, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Front Oncol：不可切除的III期非小细胞肺癌同期或续贯放化疗后Durvalumab维持治疗的真实世界、多中心、观察性回顾性研究, objectType=article, longId=217894, objectId=d2e921e89470, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2e921e89470, replyNumber=0, likeNumber=76, createdTime=2021-10-01, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2e921e89470, moduleTitle=Front Oncol：不可切除的III期非小细胞肺癌同期或续贯放化疗后Durvalumab维持治疗的真实世界、多中心、观察性回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2e921e89470)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287974, encodeId=e8ac128e97411, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Front Oncol：可切除胰腺癌伴有淋巴结转移或R1切除使用辅助化疗续贯放化疗的疗效评估, objectType=article, longId=217585, objectId=6b7921e585b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b7921e585b6, replyNumber=0, likeNumber=65, createdTime=2021-09-26, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b7921e585b6, moduleTitle=Front Oncol：可切除胰腺癌伴有淋巴结转移或R1切除使用辅助化疗续贯放化疗的疗效评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b7921e585b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287973, encodeId=ede1128e9735b, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=放化疗后，度伐利尤单抗的使用‌引起了肺癌患者的哮喘, objectType=article, longId=216059, objectId=8d11216059d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d11216059d4, replyNumber=0, likeNumber=69, createdTime=2021-08-22, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d11216059d4, moduleTitle=放化疗后，度伐利尤单抗的使用‌引起了肺癌患者的哮喘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d11216059d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287972, encodeId=1a36128e97274, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Gastroenterology：颠覆！T1bN0M期食管鳞癌患者采用放化疗治疗的效果不劣于手术！, objectType=article, longId=215857, objectId=3a0b21585eec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a0b21585eec, replyNumber=0, likeNumber=93, createdTime=2021-08-18, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a0b21585eec, moduleTitle=Gastroenterology：颠覆！T1bN0M期食管鳞癌患者采用放化疗治疗的效果不劣于手术！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a0b21585eec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287971, encodeId=b76d128e971d4, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=JAMA Oncol：二甲双胍联合同步放化疗治疗局部晚期非小细胞肺癌（NRG-LU001研究，附点评）, objectType=article, longId=215628, objectId=4ff021562880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ff021562880, replyNumber=0, likeNumber=66, createdTime=2021-08-14, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ff021562880, moduleTitle=JAMA Oncol：二甲双胍联合同步放化疗治疗局部晚期非小细胞肺癌（NRG-LU001研究，附点评）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ff021562880)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287970, encodeId=775c128e970d1, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=肺癌三期不可手术的患者NSCLC体质差的，是否可以不做同步放化疗，直接化疗后免疫维持？, objectType=article, longId=214836, objectId=488c2148364c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=488c2148364c, replyNumber=0, likeNumber=74, createdTime=2021-07-28, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=488c2148364c, moduleTitle=肺癌三期不可手术的患者NSCLC体质差的，是否可以不做同步放化疗，直接化疗后免疫维持？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=488c2148364c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1287969, encodeId=735e128e969b8, content=<a href='/topic/show?id=4d185e31825' target=_blank style='color:#2F92EE;'>#放化疗#</a>, objectTitle=Clinical Lung Cancer：老年不可切除III期非小细胞肺癌（NSCLC）患者同步放化疗后Durvalumab维持治疗的疗效：PACIFIC研究事后分析, objectType=article, longId=213772, objectId=b27f213e7214, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b27f213e7214, replyNumber=0, likeNumber=73, createdTime=2021-07-07, rootId=0, userName=yzh399, userId=310e209, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b27f213e7214, moduleTitle=Clinical Lung Cancer：老年不可切除III期非小细胞肺癌（NSCLC）患者同步放化疗后Durvalumab维持治疗的疗效：PACIFIC研究事后分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b27f213e7214)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

放化疗

2020-05-29

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Front Oncol：奈达铂 vs 顺铂为基础的同期放化疗治疗IIB-IVA期宫颈癌患者的疗效和安全性

2022-02-06

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

J Clin Oncol：PACIFIC研究5年生存结果提示放化疗后durvalumab（德瓦鲁单抗）持续改善III期NSCLC患者的预后，5年OS超过40%

2022-02-05

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

JAMA Oncol：3期随机试验 | 序贯放化疗 vs 同步放化疗用作早期宫颈癌术后辅助治疗的疗效

2021-12-30

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Cancer：HIV-1蛋白酶抑制剂奈非那韦联合标准放化疗治疗局部晚期宫颈癌的效果

2021-12-30

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Ann Oncol：局限期小细胞肺癌(LD-SCLC)患者同步放化疗+PCI后使用nivolumab+ipilimumab免疫联合强化治疗并不能改善患者的预后

2021-12-28

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

JAMA Netw Open：中肿麦海强教授团队证实奈达铂为基础的同期放化疗可作为II-IVB期鼻咽癌患者的有效治疗方案

2021-12-24

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

DCR: 慢性肾脏病对接受新辅助放化疗治疗的局部晚期直肠癌患者的预后影响

2021-12-14

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Front Oncol：比较同步放化疗联合诱导化疗或辅助化疗在II–IVA期鼻咽癌患者中的疗效和安全性

2021-12-05

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

JAMA Oncol：局部晚期结直肠癌的全新辅助疗法——放化疗+诱导/巩固化疗！

2021-12-03

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

EP 方案同步放化疗治疗局限期小细胞肺癌的疗效分析

2021-11-22

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Front Oncol：新辅助同步放化疗(nCRT)对可切除Siewert II型或III型胃食管交界处腺癌(AEG)的长期疗效影响

2021-11-16

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

J Clin Oncol：儿童放化疗后，听力损失的发生率和风险因素调查

2021-10-24

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Cancers：早期乳腺癌患者新辅助放化疗的长期疗效和安全性

2021-10-20

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Front Oncol：不可切除的III期非小细胞肺癌同期或续贯放化疗后Durvalumab维持治疗的真实世界、多中心、观察性回顾性研究

2021-10-01

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Front Oncol：可切除胰腺癌伴有淋巴结转移或R1切除使用辅助化疗续贯放化疗的疗效评估

2021-09-26

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

放化疗后，度伐利尤单抗的使用‌引起了肺癌患者的哮喘

2021-08-22

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Gastroenterology：颠覆！T1bN0M期食管鳞癌患者采用放化疗治疗的效果不劣于手术！

2021-08-18

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

JAMA Oncol：二甲双胍联合同步放化疗治疗局部晚期非小细胞肺癌（NRG-LU001研究，附点评）

2021-08-14

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

肺癌三期不可手术的患者NSCLC体质差的，是否可以不做同步放化疗，直接化疗后免疫维持？

2021-07-28

yzh399 (审核中...)

前往app查看评论内容

#放化疗#

Clinical Lung Cancer：老年不可切除III期非小细胞肺癌（NSCLC）患者同步放化疗后Durvalumab维持治疗的疗效：PACIFIC研究事后分析

2021-07-07

科室
- - 订阅+
  - 更多科室
工具
服务